title: Acceptability of offering financial incentives to achieve medication adherence in patients with severe mental illness: a focus group study.
abstract: BACKGROUND
  Offering financial incentives to achieve medication adherence in patients with severe mental illness is controversial.
  
  
  OBJECTIVE
  To explore the views of different stakeholders on the ethical acceptability of the practice.
  
  
  METHODS
  Focus group study consisting of 25 groups with different stakeholders.
  
  
  RESULTS
  Eleven themes dominated the discussions and fell into four categories: (1) 'wider concerns', including the value of medication, source of funding, how patients would use the money, and a presumed government agenda behind the idea; (2) 'problems requiring clear policies', comprising of practicalities and assurance that incentives are only one part of a tool kit; (3) 'challenges for research and experience', including effectiveness, the possibility of perverse incentives, and impact on the therapeutic relationship; (4) 'inherent dilemmas' around fairness and potential coercion.
  
  
  CONCLUSIONS
  The use of financial incentives is likely to raise similar concerns in most stakeholders, only some of which can be addressed by empirical research and clear policies.
authors.affiliation: Queen Mary University of London, Unit for Social and Community Psychiatry, Newham Centre for Mental Health, London, UK. s.priebe@qmul.ac.uk
authors.forename: Stefan
authors.initials: S
authors.lastname: Priebe
authors.forename: Julia
authors.initials: J
authors.lastname: Sinclair
authors.forename: Alexandra
authors.initials: A
authors.lastname: Burton
authors.forename: Stamatina
authors.initials: S
authors.lastname: Marougka
authors.forename: John
authors.initials: J
authors.lastname: Larsen
authors.forename: Mike
authors.initials: M
authors.lastname: Firn
authors.forename: Richard
authors.initials: R
authors.lastname: Ashcroft
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D017144:Focus Groups; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D001523:Mental Disorders / Q000188:drug therapy* / Q000191:economics; D008875:Middle Aged; D009042:Motivation; D012201:Reward; D006113:United Kingdom; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents